Patents by Inventor Nikolaj Kulahin Roed

Nikolaj Kulahin Roed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for treatment of obesity
    Patent number: 11753455
    Abstract: The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: September 12, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Nikolaj Kulahin Roed, Michael Paolo Bastner Sandrini, Jesper Lau, Paw Bloch, Anna Secher, Adam Paul Chambers, Jim McGuire, Lotte Bjerre Knudsen
  • NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF
    Publication number: 20230233650
    Abstract: Ucn2 derivatives comprising a peptide and a substituent with high potency, high physical and high chemical stability, suitable for administration to humans, and their medical use in treatment and/or prevention of obesity and/or diabetes.
    Type: Application
    Filed: July 15, 2022
    Publication date: July 27, 2023
    Inventors: Chien Li, Nicholas Raymond Cox, Jason O'Neil, Patrick William Garibay, Berit Christoffersen Gyrstinge, Hans Dennis Aasberg, Lennart Lykke, Nikolaj Kulahin Roed
  • NOVEL COMPOUNDS FOR TREATMENT OF OBESITY
    Publication number: 20210261641
    Abstract: The invention relates to a construct comprising a compound targeting areas in the brain involved in the regulation of body weight and an allosteric ligand to a receptor located in the blood-brain barrier (BBB). The invention also relates to compositions and uses of such construct, for example in the prevention or treatment of overweight and obesity. Preferred compounds for regulation of body weight include GLP-1 receptor agonists (GLP-1RA), and preferred receptors located in the BBB include the transferrin receptor (TfR). Exemplary fusions and conjugates of GLP-1 RA's and anti TfR-Fab's exhibit an increased binding to brain regions expressing the GLP-1 receptor as compared to fusions or conjugates with inactive control Fab's, in particular in brain areas protected by the BBB. In vivo mice studies confirm increased reduction in food intake as well as weight loss for the active construct compared to the inactive one.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 26, 2021
    Inventors: Nikolaj Kulahin Roed, Michael Paolo Bastner Sandrini, Jesper Lau, Paw Bloch, Anna Secher, Adam Paul Chambers, Jim McGuire, Lotte Bjerre Knudsen